Shanghai Haohai Biological Technology Co (HKSE:06826) Debt-to-Equity : 0.04 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Shanghai Haohai Biological Technology Co Debt-to-Equity?

Shanghai Haohai Biological Technology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$11 Mil. Shanghai Haohai Biological Technology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$220 Mil. Shanghai Haohai Biological Technology Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was HK$6,252 Mil. Shanghai Haohai Biological Technology Co's debt to equity for the quarter that ended in Mar. 2024 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Shanghai Haohai Biological Technology Co's Debt-to-Equity or its related term are showing as below:

HKSE:06826' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.07
Current: 0.04

During the past 10 years, the highest Debt-to-Equity Ratio of Shanghai Haohai Biological Technology Co was 0.07. The lowest was 0.01. And the median was 0.02.

HKSE:06826's Debt-to-Equity is ranked better than
77.09% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs HKSE:06826: 0.04

Shanghai Haohai Biological Technology Co Debt-to-Equity Historical Data

The historical data trend for Shanghai Haohai Biological Technology Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Haohai Biological Technology Co Debt-to-Equity Chart

Shanghai Haohai Biological Technology Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.02

0.07

Shanghai Haohai Biological Technology Co Quarterly Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															N/A	0.04	0.05	0.07	0.04

Competitive Comparison of Shanghai Haohai Biological Technology Co's Debt-to-Equity

For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Haohai Biological Technology Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Haohai Biological Technology Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Shanghai Haohai Biological Technology Co's Debt-to-Equity falls into.

Shanghai Haohai Biological Technology Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Shanghai Haohai Biological Technology Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(236.94	+	209.266)	/	6179.921
	=	0.07

Shanghai Haohai Biological Technology Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.863	+	220.326)	/	6251.74
	=	0.04

Shanghai Haohai Biological Technology Co (HKSE:06826) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Shanghai Haohai Biological Technology Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Shanghai Haohai Biological Technology Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Haohai Biological Technology Co (HKSE:06826) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Haohai Biological Technology Co Ltd (HKSE:06826) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

688366:China

Address

No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN

Website

https://www.3healthcare.com

Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. It is also engaged in the research and development of biological engineering, pharmaceutical and ophthalmology products, and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries.

Shanghai Haohai Biological Technology Co (HKSE:06826) Headlines

No Headlines